Talis Biomedical Corp Stock EBITDA
Talis Biomedical Corp fundamentals help investors to digest information that contributes to Talis Biomedical's financial success or failures. It also enables traders to predict the movement of Talis Pink Sheet. The fundamental analysis module provides a way to measure Talis Biomedical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Talis Biomedical pink sheet.
Talis |
Talis Biomedical Corp Company EBITDA Analysis
Talis Biomedical's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Talis Biomedical EBITDA | (60.7 M) |
Most of Talis Biomedical's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Talis Biomedical Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
CompetitionAccording to the company disclosure, Talis Biomedical Corp reported earnings before interest,tax, depreciation and amortization of (60.7 Million). This is 106.92% lower than that of the Health Care Equipment & Supplies sector and 109.45% lower than that of the Health Care industry. The ebitda for all United States stocks is 101.56% higher than that of the company.
Talis EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Talis Biomedical's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Talis Biomedical could also be used in its relative valuation, which is a method of valuing Talis Biomedical by comparing valuation metrics of similar companies.Talis Biomedical is currently under evaluation in ebitda category among its peers.
Talis Fundamentals
| Return On Equity | -0.7 | ||||
| Return On Asset | -0.3 | ||||
| Operating Margin | (113.60) % | ||||
| Current Valuation | (38.24 M) | ||||
| Shares Outstanding | 1.82 M | ||||
| Shares Owned By Insiders | 8.30 % | ||||
| Shares Owned By Institutions | 52.15 % | ||||
| Number Of Shares Shorted | 17.96 K | ||||
| Price To Book | 0.06 X | ||||
| Price To Sales | 19.57 X | ||||
| Revenue | 412 K | ||||
| Gross Profit | (149.4 M) | ||||
| EBITDA | (60.7 M) | ||||
| Net Income | (62.01 M) | ||||
| Cash And Equivalents | 165.37 M | ||||
| Cash Per Share | 6.21 X | ||||
| Total Debt | 19.67 M | ||||
| Debt To Equity | 0.19 % | ||||
| Current Ratio | 12.51 X | ||||
| Book Value Per Share | 26.68 X | ||||
| Cash Flow From Operations | (53.24 M) | ||||
| Short Ratio | 0.59 X | ||||
| Earnings Per Share | (28.02) X | ||||
| Target Price | 5.0 | ||||
| Number Of Employees | 99 | ||||
| Beta | 1.62 | ||||
| Market Capitalization | 7.98 M | ||||
| Total Asset | 98.34 M | ||||
| Retained Earnings | (539.96 M) | ||||
| Working Capital | 68.91 M | ||||
| Net Asset | 98.34 M |
Thematic Opportunities
Explore Investment Opportunities
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Other Consideration for investing in Talis Pink Sheet
If you are still planning to invest in Talis Biomedical Corp check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Talis Biomedical's history and understand the potential risks before investing.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |